proteoglycan 3, pro eosinophil major basic protein 2Genealiases: MBP2 · MBPH
Q-omics provides the consensus-scored PRG3 profile across patient tissues and cancer cell-line models. PRG3 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PRG3 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, PRG3 protein abundance shows 9,693 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KIRP, and LSCC as cancer lineages where PRG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRG3 survival associations across molecular data types. PRG3 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRG3 RNA expression–survival associations across cancer types. High PRG3 expression shows unfavorable associations in LUSC, BLCA, READ, MESO, GBM and KIRC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for PRG3 RNA expression.
This table summarizes PRG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRG3 shows lower tumor expression in STAD and higher tumor expression in KIRP and COAD. The KIRP box plot shows higher PRG3 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .030).
This table shows molecular features associated with PRG3 in patient tissues and cancer cell lines. In patient samples, PRG3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
